Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KLKB1 | P03952 | 18/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.52 |
| ▸ | F9 | P00740 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18605173 | 0.87 | KLKB1 (0.58) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL17064543 | 0.87 | KLKB1 (0.54) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL31067480 | 0.87 | KLKB1 (0.58) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL31067479 | 0.87 | KLKB1 (0.54) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL25179508 | 0.86 | KLKB1 (0.69) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL31744232 | 0.84 | KLKB1 (0.74) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL17065041 | 0.84 | KLKB1 (0.74) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL3830293 | 0.84 | F10 (0.65) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL18604747 | 0.83 | KLKB1 (0.59) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL31067612 | 0.82 | KLKB1 (0.60) | KLKB1PLGPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6465656-B2 | ACYLATING/ACETYLATING ARYLHYDRAZINE, REACTING HYDROZONOYL HALIDE/SULFATE WITH AMINE BASE TO FORM 1-(3-CYANO)PHENYL-2-(TRIFLUOROACETYL)HYDRAZINE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-15 | — | — | US | disclosed |
| EP-1222172-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-09 | — | — | US | disclosed |
| US-6329527-B1 | ACYLATING SUBSTITUTEDARYL HYDRAZINE, FORMING DIPOLAR COMPOUND, CONTACTING DIPOLAROPHILE AND SUBJECTING TO OXIDATION, REMOVING PROTECTING GROUP | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-11 | — | — | US | disclosed |
| WO-2001029006-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | TFPI, SERPINC1, F11 | KMT2A 3250/4885KLKB1 277/4885PLG 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.